How to Get Testosterone Enanthate in Virginia

Who Can Prescribe Testosterone Enanthate in Virginia

Any licensed physician (MD or DO) in Virginia can prescribe testosterone enanthate for male hypogonadism. Nurse practitioners and physician assistants may also prescribe this Schedule III controlled substance under Virginia's collaborative practice laws, though NPs practicing independently must hold a practice agreement on file with the Virginia Board of Nursing.

Virginia adopted the Interstate Medical Licensure Compact, which means physicians licensed through the Compact in another member state can obtain a Virginia license on an expedited basis. This expands the pool of telehealth prescribers available to Virginia residents. The Virginia Board of Medicine requires that any prescriber ordering a controlled substance maintain a bona fide patient-provider relationship, which can be established via a synchronous telehealth visit under Virginia Code § 54.1-3303.

For men seeking a specialist, endocrinologists and urologists are the most common prescribers of testosterone replacement therapy (TRT). The Endocrine Society's 2018 clinical practice guideline recommends that testosterone therapy be prescribed only to men with "unequivocally low serum testosterone concentrations" combined with clinical symptoms such as reduced libido, fatigue, or loss of muscle mass 1.

Primary care providers prescribe TRT frequently as well. A 2017 analysis published in JAMA Internal Medicine found that primary care physicians accounted for the largest share of testosterone prescriptions in the United States, outnumbering urologists and endocrinologists combined 2.

Lab Requirements Before Starting Treatment

Virginia prescribers follow national guidelines requiring laboratory confirmation of hypogonadism before initiating testosterone enanthate. Two separate morning total testosterone measurements below the laboratory's lower reference limit form the diagnostic foundation. The Endocrine Society defines this threshold as total testosterone below 300 ng/dL (10.4 nmol/L) on most commercial assays 1.

Blood draws should occur between 7:00 a.m. and 10:00 a.m. Testosterone follows a circadian rhythm, peaking in early morning and declining by 20 to 25% by late afternoon, according to data published in the Journal of Clinical Endocrinology & Metabolism 3. A single low reading is not sufficient because day-to-day variability in testosterone levels can reach 15 to 20%.

Beyond total testosterone, most Virginia providers order a baseline panel that includes:

• Free testosterone (calculated or measured by equilibrium dialysis)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to differentiate primary from secondary hypogonadism
• Complete blood count (CBC) with hematocrit, because testosterone can raise red blood cell production
• Comprehensive metabolic panel including liver function
• Prostate-specific antigen (PSA) in men over 40
• Lipid panel

The American Urological Association's 2018 guideline states: "Clinicians should measure a total testosterone level in patients with signs or symptoms of testosterone deficiency and use a total testosterone level below 300 ng/dL as a reasonable cut-off" 4. Some telehealth platforms operating in Virginia will order labs through national draw networks such as Quest Diagnostics or Labcorp, both of which operate dozens of patient service centers across the Commonwealth.

Telehealth Access for Testosterone Enanthate in Virginia

Virginia law permits testosterone enanthate prescriptions via telehealth. The state updated its telehealth regulations during the COVID-19 pandemic and made many expansions permanent. A synchronous audio-video visit satisfies the patient-provider relationship requirement for Schedule III prescriptions in Virginia.

Several national telehealth TRT platforms are licensed in Virginia and follow a standardized workflow: the patient completes a health questionnaire, provides or completes lab work, has a video consultation with a licensed prescriber, and receives a prescription sent to a pharmacy of choice. Turnaround from initial signup to first injection typically ranges from 7 to 21 days depending on lab scheduling.

The DEA requires that any prescriber issuing a controlled substance via telehealth be registered with the DEA in the state where the patient is located, or hold a valid exception under the DEA's telemedicine practice rules. Virginia-based prescribers must carry an active Virginia Controlled Substance Registration (CSR) alongside their DEA registration 5.

One advantage of telehealth for Virginia residents in rural areas is geographic reach. The Virginia Department of Health reports that 59 of the state's 133 counties and independent cities are designated Health Professional Shortage Areas (HPSAs) for primary care. Telehealth eliminates the need to drive hours for an endocrinology appointment, which can carry wait times exceeding two months in underserved regions.

Pharmacy Options: Retail vs. 503A Compounding

Virginia residents filling a testosterone enanthate prescription have two primary dispensing pathways.

Retail pharmacy. Brand-name Delatestryl and generic testosterone enanthate are available at CVS, Walgreens, Kroger, and independent pharmacies across Virginia. A 5 mL vial of 200 mg/mL generic testosterone enanthate (1 to 000 mg total) typically costs $40 to $90 without insurance, based on GoodRx estimates for Virginia ZIP codes. With commercial insurance or a manufacturer coupon, out-of-pocket cost drops further.

503A compounding pharmacy. Virginia licenses 503A compounding pharmacies under the Virginia Board of Pharmacy. These pharmacies can compound testosterone enanthate in customized concentrations (for example, 250 mg/mL) or in combination with other compounds when a prescriber determines a medical need. Virginia-licensed 503A pharmacies may ship compounded testosterone enanthate to patients within the state but cannot distribute across state lines without 503B outsourcing facility registration with the FDA 6.

A key distinction: 503A pharmacies compound pursuant to individual patient prescriptions, while 503B outsourcing facilities can produce larger batches without patient-specific prescriptions. For most Virginia TRT patients, a 503A pharmacy offers the flexibility of custom dosing at competitive pricing, often between $30 and $70 per month for a standard 200 mg/week regimen.

Virginia Medicaid and Insurance Coverage

Virginia Medicaid covers testosterone enanthate for the indication of male hypogonadism, but requires prior authorization (PA). The PA process verifies that the patient meets clinical criteria: documented low testosterone on two morning draws, presence of clinical symptoms, and absence of contraindications such as untreated polycythemia, severe sleep apnea, or active prostate cancer.

The Virginia Department of Medical Assistance Services (DMAS) Preferred Drug List places testosterone enanthate on the formulary. Prescribers or their staff submit the PA request electronically or by fax. Approval timelines typically run 24 to 72 hours for standard requests, with a 24-hour turnaround required for urgent requests under federal Medicaid rules.

For commercial insurance, most major plans in Virginia (Anthem, Aetna, Cigna, Optima Health) cover generic testosterone enanthate at Tier 2 or Tier 3 copay levels. Step therapy requirements vary. Some insurers require documentation that the patient tried topical testosterone (gels or patches) before approving injectable testosterone enanthate, though a prescriber can often override this with a clinical justification citing patient preference for stable serum levels or cost considerations.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine, demonstrated that testosterone treatment in men 65 and older with low testosterone improved sexual function, physical activity, and mood 7. These findings, drawn from 790 men over 12 months, strengthened the evidence base that insurers use when evaluating coverage for testosterone replacement in older men.

What to Expect: Dosing and Monitoring in Virginia

The standard testosterone enanthate regimen for male hypogonadism is 100 to 200 mg administered as an intramuscular injection once weekly or 200 to 400 mg every two weeks. The FDA-approved labeling for testosterone enanthate lists dosing ranges of 50 to 400 mg every two to four weeks depending on clinical response 8. Most clinicians now favor weekly injections at lower individual doses because this produces more stable serum testosterone levels and fewer troughs that cause symptom recurrence.

Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School and author of Testosterone for Life, has stated: "Weekly injections of testosterone enanthate provide more physiologic testosterone levels compared with every-two-week dosing, and patients consistently report fewer mood swings and energy dips."

After initiating therapy, Virginia prescribers typically schedule follow-up labs at 6 to 12 weeks. The monitoring panel includes:

• Total testosterone (drawn at trough, the morning before the next injection)
• Hematocrit (therapy should be held if hematocrit exceeds 54%, per Endocrine Society guidelines 1)
• PSA in men over 40
• Estradiol if symptoms of estrogen excess appear

Once stable, monitoring shifts to every 6 to 12 months. A 2019 meta-analysis in The Lancet Diabetes & Endocrinology covering 35 trials and over 5,500 men found that testosterone therapy did not increase the risk of major adverse cardiovascular events in men with hypogonadism 9. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, confirmed that testosterone replacement in men aged 45 to 80 with hypogonadism and cardiovascular risk factors was noninferior to placebo for major adverse cardiovascular events 10.

Prior Authorization Documentation for Virginia Payers

When a Virginia insurer or Medicaid requires prior authorization for testosterone enanthate, the prescriber must submit specific documentation. Incomplete submissions are the most common cause of PA denials and delays.

A complete PA package for Virginia payers typically includes:

1. Two morning total testosterone results with lab dates and reference ranges
2. Clinical symptoms documented in the chart (reduced libido, fatigue, decreased muscle mass, depressed mood, or erectile dysfunction)
3. Diagnosis code (ICD-10 E29.1 for primary hypogonadism or E23.0 for secondary)
4. Contraindication screening confirming no untreated severe obstructive sleep apnea, active polycythemia (hematocrit above 50%), or known hormone-sensitive malignancy
5. Prior therapy documentation if step therapy applies (e.g., trial of topical testosterone with reason for discontinuation)

The AUA guideline notes: "In patients with borderline testosterone values (between 250 and 350 ng/dL), clinicians should consider repeating testosterone measurements and evaluating free or bioavailable testosterone" 4. Including free testosterone values in the PA submission strengthens the case for patients whose total testosterone sits near the threshold.

Virginia Medicaid allows prescribers to appeal denied PA requests within 30 days. The appeal must include additional clinical rationale or supporting documentation not present in the original submission. Commercial insurers in Virginia follow similar timelines, with most requiring external review completion within 45 days for non-urgent cases.

Transferring a Testosterone Enanthate Prescription to Virginia

Patients relocating to Virginia can transfer an existing testosterone enanthate prescription from another state if the prescription has remaining refills and the receiving Virginia pharmacy can verify its validity. Because testosterone enanthate is a Schedule III controlled substance, federal law (21 CFR § 1306.25) permits the transfer of a prescription between pharmacies only once, unless both pharmacies share a real-time electronic database.

Patients moving to Virginia with an established TRT regimen from another state should:

• Request a copy of recent lab results and prescriber notes from their current provider
• Establish care with a Virginia-licensed prescriber (in person or via telehealth)
• Provide the new prescriber with their treatment history, including current dose, frequency, and duration on therapy
• Have the new prescriber write a fresh Virginia prescription rather than relying on a one-time transfer

This approach avoids complications with controlled substance transfer limits and ensures continuity. Most Virginia telehealth TRT platforms can onboard transfer patients within 5 to 10 business days if recent labs (within the past 90 days) are available.